Overview

Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients

Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
This study will examine the long-term safety and efficacy of Deferasirox in patients with sickle cell disease and iron overload from repeated blood transfusions.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Deferasirox
Deferoxamine